🟠 Conducted across 95 global sites with 1,287 participants, the trial evaluated monthly doses of 150 mg and 90 mg abelacimab against standard rivaroxaban treatment. 
#CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA